PF-00562271 suppressed the WST-8 proliferation response of collagen-plated KU-Lu-MPPt3 CS cells during a four-day assay. The paper does not specify the PF-00562271 concentration for this experiment, preventing a dose-specific potency claim. [1]
In pancreatic MPanc-96 and MAD08-608 cultures, the authors reported that PF-562,271 up to 1 µM did not inhibit proliferation or enhance gemcitabine-mediated growth inhibition. The growth panel extends to 10 µM, where the cell-number signal falls; the negative result applies to the stated lower concentration range and culture conditions. [2]
In a three-dimensional PDAC 608 tumor microenvironment system, 5.8 µM PF-562,271 for three days reduced total tumor/stellate cell-number signal by 49% and tumor-specific EdU incorporation by 67% versus DMSO. These endpoints measure different cell populations. This experiment supports activity in that multicellular model, without establishing the cause of differences from two-dimensional culture. [3]
FAK and Akt phosphorylation in lung adenocarcinoma cells
Cell-based study · KU-Lu-MPPt3 clumpy and suspended (CS) cells [1]
PF-00562271 reduced p-FAK/total FAK while increasing p-Akt/total Akt relative to control. Akt inhibitor X was a separate comparator, not a combination treatment.
Literature-Reported Treatment Conditions
- Method
- Western blotting with p-FAK Tyr397, p-Akt Ser473, total FAK, total Akt and actin controls.
- Reported limits
- PF-00562271 concentration, signaling exposure duration, vehicle, counterion and lot are not specified in the relevant main-text methods/caption.
Methods and source locations
Compound reported in the paper: PF-00562271
Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.
Figure 5A/B; Antibodies and inhibitors; Western blot analysis; Results: Involvement of Akt and FAK in adhesion and proliferation
FAK Tyr397 and Akt Ser473 phosphorylation normalized to corresponding total protein: Immunoblot and band quantification; no exact bar-height values inferred. — Figure 5A/B and caption; Western blot analysis
Proliferation response in KU-Lu-MPPt3 CS cells
Cell-based study · KU-Lu-MPPt3 CS cells on collagen-coated 96-well plates [1]
Untreated cells expanded, whereas PF-00562271 suppressed the WST-8 proliferation signal over the four-day assay. This readout does not establish cell death.
Literature-Reported Treatment Conditions
- Exposure duration
- 4 days
- Method
- WST-8/CCK-8 absorbance at 450 nm; untreated control and separate Akt inhibitor X comparator.
- Reported limits
- PF-00562271 concentration and vehicle are not specified in the relevant main text/caption; no IC50 can be assigned.
Methods and source locations
Compound reported in the paper: PF-00562271
Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.
Figure 5C and caption; Cell proliferation assay; Results: Involvement of Akt and FAK in adhesion and proliferation
WST-8 proliferation ratio compared with untreated culture: WST-8 readout; no exact values digitized from the time course. — Figure 5C and caption; Cell proliferation assay
Limited antiproliferative activity in pancreatic cell cultures
Cell-based study · MPanc-96 and MAD08-608 pancreatic ductal adenocarcinoma cultures, as described jointly in Results; Figure 3C is the representative main-text growth panel. [2]
The Results report no proliferation inhibition by PF-562,271 at up to 1 µM, alone or with gemcitabine, despite inhibition of FAK signaling/migration at lower concentrations in separate assays. Figure 3C includes a 10 µM point with a lower cell-number signal; the negative finding is therefore restricted to ≤1 µM.
Literature-Reported Treatment Conditions
- Treatment concentration
- PF-562,271: 0.001, 0.01, 0.1, 1 and 10 µM in Figure 3C; negative proliferation conclusion restricted to ≤1 µM.
- Method
- CyQuant cell-number assay in 1% FBS-containing medium.
- Co-treatment
- Parallel gemcitabine series: 1, 10 and 100 ng/mL; PF-562,271 tested alone and with gemcitabine.
- Reported limits
- Proliferation exposure duration, vehicle composition and replicate number are not specified in the selected main-text assay/caption. MAD08-608 supplemental plot was not retrieved.
Methods and source locations
Compound reported in the paper: PF-562,271
Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.
Figure 3C and caption; Results: PDA cell receptor signaling, migration and invasion; Transwell migration, invasion and proliferation assays
Pancreatic cell proliferation alone or with gemcitabine: CyQuant; figure error bars denote standard error; n not specified in caption. — Results paragraph beginning “We evaluated the effects”; Figure 3C; proliferation methods
PF-562,271 response in a pancreatic tumor microenvironment system
Cell-based study · PDAC 608 patient-derived tumor cells with primary human pancreatic stellate cells and microvascular endothelial cells in a three-dimensional TMES under tumor-like hemodynamics. [3]
PF-562,271 reduced total tumor/stellate cell-number signal and tumor-specific EdU incorporation versus DMSO. These are complementary endpoints from one exposure experiment, not independent studies.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5.8 µM PF-562,271
- Exposure duration
- 3 days of treatment after 4 days of TMES growth
- Method
- PicoGreen total-cell DNA surrogate and EdU co-imaged with cytokeratin 18 for tumor-specific proliferation.
- Vehicle
- DMSO (0.058%)
- Reported limits
- Exact salt form, supplier and lot are not specified in selected main-text methods. TMES lacks immune cells; no clinical response to PF-562,271 was tested.
Methods and source locations
Compound reported in the paper: PF-562,271
Results concern the named material and model reported by the authors; no salt conversion, exact salt equivalence or validation of an Adooq lot is claimed.
Figure 5A/B and caption; PF-562,271 Results; Methods: Cell culture, Tumor Microenvironment System, Immunofluorescence
Total tumor-plus-stellate cell number per unit area: PicoGreen with standard curve; Figure 5 caption specifies N=3 with five independent measurements across each transwell replicate, not 15 independent biological replicates. — Figure 5A/caption and PF-562,271 Results
Tumor-specific proliferating fraction: EdU incorporation co-imaged with cytokeratin 18; N=3 with five measurements across each transwell replicate; EdU pulse for final 2 hours. — Figure 5B/caption; Methods: Tumor Microenvironment System and Immunofluorescence